Molecular Partners AG (MOLN)
4.40
+0.62
(+16.37%)
USD |
NASDAQ |
May 01, 15:38
Molecular Partners Cash from Investing (TTM): 49.71M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 49.71M |
September 30, 2023 | 64.36M |
June 30, 2023 | 15.78M |
March 31, 2023 | -1.095M |
December 31, 2022 | -106.03M |
Date | Value |
---|---|
September 30, 2022 | -131.10M |
June 30, 2022 | -128.91M |
March 31, 2022 | -126.08M |
December 31, 2021 | -24.33M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-131.10M
Minimum
Sep 2022
64.36M
Maximum
Sep 2023
-43.08M
Average
-24.33M
Median
Dec 2021
Cash from Investing (TTM) Benchmarks
AC Immune SA | 73.11M |
CRISPR Therapeutics AG | 374.65M |
Addex Therapeutics Ltd | -0.0076M |
NLS Pharmaceutics Ltd | -- |
MoonLake Immunotherapeutics | -25.18M |